CN103230421A - Administration method for treating respiratory tract infections - Google Patents
Administration method for treating respiratory tract infections Download PDFInfo
- Publication number
- CN103230421A CN103230421A CN2012103984944A CN201210398494A CN103230421A CN 103230421 A CN103230421 A CN 103230421A CN 2012103984944 A CN2012103984944 A CN 2012103984944A CN 201210398494 A CN201210398494 A CN 201210398494A CN 103230421 A CN103230421 A CN 103230421A
- Authority
- CN
- China
- Prior art keywords
- respiratory tract
- virus
- oral
- administration method
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to an administration method for treating respiratory tract infections. The infection diseases include influenza virus and common cold virus, and secondary bacterial infection which is respiratory tract infection (viral and/or bacterial). Traditional oral administration method is unreasonable, and should be changed into oral mucosa or sublingual administration. Especially, for traditional Chinese herbal medicine preparations comprising both anti-cold-virus components and antibacterial components, preparation and administration method reformation are carried out, such that anti-infective preventive effects of the traditional Chinese herbal medicine are sufficiently developed. Therefore, traditional Chinese herbal medicine research and development can be greatly promoted.
Description
Technical field
The present invention relates to about treatment respiratory tract infection disease (virus and/or antibacterial) used traditional oral methods unreasonablely, must change.
Background technology
Except do not absorb at gastrointestinal tract or ruined medicine, nearly all medicine is all made preparations such as the tablet, capsule, soft gelatin capsule, granule, solution of various oral administrations, and these preparations owner wants composition to be absorbed the back to send ill histoorgan to blood flow and play therapeutical effect.Because these oral formulations are taken safe ready, dosage is relatively accurate.Oral drugs seldom cause allergic reaction, and almost do not see the burst anaphylactic shock, and drug oral is very popular, unmanned blame.
Just because of oral medicine is with unmanned blame, no matter be that Chinese medicine or western medicine and medical practitioners have been made traditional mistake over a long time in the treatment of some diseases.
Summary of the invention
The traditional oral administration method of the treatment respiratory tract infection disease that purpose of the present invention is mainly corrected a mistake (virus or antibacterial).
The present invention will solve following several problem:
1, many to the research of the anti-cold virus of Chinese herbal medicine, as Radix Isatidis (Folium Isatidis) Rhizoma Osmundae, Radix Et Rhizoma Rhei, Radix Arnebiae (Radix Lithospermi), Rhizoma Polygoni Cuspidati, Herba Andrographis etc., laboratory research is all inhibited to influenza virus.But do not have clinical practical validation, probably problem is just for adopting on traditional safest oral medication method.Each influenza one, Chinese herbal medicine such as Radix Isatidis, Rhizoma Osmundae, Rhizoma Polygoni Cuspidati consume in a large number, and not seeing has any positive effect, the generation of uncontrollable influenza and development, thereby do not have any progress so far.
Influenza virus begins to be adsorbed on epithelial cell in upper respiratory tract infection, penetrates (entering in the cell), sloughs shell, biosynthesis and assembling, finishes this several stages and needs 8 hours approximately, namely finishes copying of progeny virus.So arranged the incubation period of a morbidity, symptom was lassitude, fear of cold, felt cold, is off one's feed etc. early stage.If at this moment change administrated method, oral drugs are changed into oral mucosa or sublingual administration, owing to the place of medicine directly being sent to influenza infection, zero distance acts on the infection medicine ' Bingduxiao ' and prevents the flu generation except above-mentioned morbidity symptom in early stage (seeing Fig. 1).Effective equally to the common cold that coronavirus, rhinovirus, respiratory syncytial virus, adenovirus etc. cause, if but adhere to that use oral administration, then the medicine overwhelming majority consumes operation process in vivo, seldom enter upper respiratory tract, do not play the anti-effect of curing cold (seeing Fig. 2) at all
2, often take place clinically below more serious sequela: pharyngolaryngitis, have that the foreign body sensation cough is more than, the patient feels deeply and feels bad, after General Symptoms disappears, and local symptom increases the weight of, before and after the flu (influenza or general sense) that Here it is, inappropriate medication, allow infection virus enter in the upper respiratory tract epithelial cell, copy breeding, make the bottleneck throat epithelial cell suffer serious destruction, causing bottleneck throat is inflamed, had a hunch that the foreign body plug does not stop in throat, cough, dry cough, no expectorant or few expectorant during beginning, sputum turns white.Afterwards color gradually flavescence similarly be purulent sputum.Illustrate that beginning is that simple virus causes, and secondary was the antibacterial inflammation afterwards, this situation does not know to have consumed how many antibiotic and coldrex.Some new Chinese herbal medicine formula in recent years, both had antivirus action, also can be to bacterial-infection resisting, but want to be prevented curing cold and the splendid curative effect of Secondary cases bacterial infection, oral administered dosage form must be changed into the dosage form of oral mucosa or sublingual administration, oral administration.
3, also have a kind of situation, must propose, because wrong oral administration allows infection virus copy breeding in epithelial cell.1 reproducible several thousand, through copying of several generations, so much progeny virus, lower respiratory tract is gone in the meeting that has unavoidably, trachea and bronchus goes.Camp there and take root, cause trachea, bronchitis, the pathogen in the oral cavity was particularly hided and also took advantage of the occasion to enliven the streptococcus pneumoniae (antibacterial that can be fatal) of nasopharynx part this moment, also going to lower respiratory tract goes And can cause the Secondary cases bacterial infection, generation trachea and bronchus inflammation, because the loss that drug oral turns round in vivo is very big, add trachea, bronchial blood vessel seldom, not as other histoorgan enriches, so enter trachea with blood flow, bronchial amount is few, does not reach useful effect concentration, so trachea, bronchitis, oral administration is not easy to cure, and becomes intractable inflammation.So oral drugs do not play antiinflammation, as with oral mucosa or sublingual administration, medicine absorbs rapidly, and is very near because of distance, oozes out the medicine of capacity very soon, can diminish inflammation.
The present invention compares with original technology, and following advantage is arranged:
1, can avoid the drug oral absorption in vivo, the loss of the exhausted major part of operation process such as metabolism, drainage and distribution and a large amount of herbal raw material waste.
2, can eliminate infection virus and Secondary cases antibacterial inflammation fast, cure flu, not stay sequela.
3, oral mucosa and Sublingual are the most intensive places of blood vessel, and drug absorption is the rapidest, not only can eliminate infection virus and the antibacterial of upper respiratory tract, and medicine that can also high concentration is followed the tracks of and run away to pulmonary, heart and brain.Near the health of these major organs protection avoids suffering the infringement of virus and pathogenic bacterium.
4, oral administration, as realize that what abnormal response or anaphylaxis are arranged, can fast medicine be spued, gargle and remove the oral cavity Chinese medicine, can remove untoward reaction, if drug oral is entered gastrointestinal tract then can't remove immediately, also will perform the preparation of antianaphylaxis.
Description of drawings
Fig. 1 eliminates the influenza virus sketch map that infects fully between momentariness behind the oral administration
Before the administration: the existing many influenza virus that infect of upper respiratory tract, 2 and 3 for influenza virus is adsorbed on the epithelial cell membrane, and 4 have just copied the progeny virus of emitting for upper respiratory tract.
After the administration: the epithelial virus of all upper respiratory tract is eliminated entirely.2 and 3 is that the virus that is adsorbed on the cell membrane has not had.4 for just having copied the progeny virus of emitting and also not had in the epithelial cell road.1 for the oral cavity is the place of administration, belongs to the area of influenza virus vital movement.
Fig. 2 is turn round the in vivo sketch map of (absorb metabolism, drain and distribute) of oral medication medicine.
1 is upper respiratory tract.2 for be adsorbed on the epithelial cell membrane infection virus and on the antibacterial of upper respiratory tract.3 medicines that enter upper respiratory tract for distributing with blood flow are few, do not work.4 is oral administration.
Claims (1)
1. the oral drugs that preventing respiratory infected (virus and/or antibacterial) change oral administration into, it is characterized in that: the various preparations of all are the existing and oral administration that preventing respiratories that will adopt infect change the dosage form that is applicable to oral administration into, oral administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012103984944A CN103230421A (en) | 2012-10-09 | 2012-10-09 | Administration method for treating respiratory tract infections |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012103984944A CN103230421A (en) | 2012-10-09 | 2012-10-09 | Administration method for treating respiratory tract infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103230421A true CN103230421A (en) | 2013-08-07 |
Family
ID=48878537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012103984944A Pending CN103230421A (en) | 2012-10-09 | 2012-10-09 | Administration method for treating respiratory tract infections |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103230421A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022033708A1 (en) * | 2020-08-14 | 2022-02-17 | Pfab Florian | Oral product comprising an antiviral active ingredient |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670506A (en) * | 2012-04-13 | 2012-09-19 | 余秀民 | Non-oral administration for influenza antiviral medicament |
-
2012
- 2012-10-09 CN CN2012103984944A patent/CN103230421A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670506A (en) * | 2012-04-13 | 2012-09-19 | 余秀民 | Non-oral administration for influenza antiviral medicament |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022033708A1 (en) * | 2020-08-14 | 2022-02-17 | Pfab Florian | Oral product comprising an antiviral active ingredient |
WO2022034234A1 (en) * | 2020-08-14 | 2022-02-17 | Pfab Florian | Oral product comprising an antiviral active ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101700307B (en) | Traditional Chinese medicine for curing chronic pharyngolaryngitis | |
CN101850008A (en) | Bacillus Ling oral liquid and preparation method thereof | |
CN101683413A (en) | Traditional Chinese medicine prescription for treating chill exterior syndrome fever and headache | |
CN101129636A (en) | Medicine for treating nasal inflammation | |
CN103768429A (en) | Traditional Chinese medicinal composition for treating acute and chronic pharyngitis and preparation method thereof | |
CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
CN108542961A (en) | Injection agent of cordate houttuynia and honeysuckle is used to prepare the purposes of rectally preparation and Neulized inhalation preparation | |
CN101822795A (en) | Medicament for treating chronic tracheitis and preparation method thereof | |
CN103230421A (en) | Administration method for treating respiratory tract infections | |
CN100569269C (en) | Analgesic | |
CN101524517A (en) | Chinese and western compound medicine for treating upper respiratory tract infection | |
CN103735679B (en) | Chinese medicine composition of a kind of diminishing inflammation and clearing pharynx and preparation method thereof | |
CN101380411A (en) | Traditional Chinese medicine preparation for relieving cough and reducing sputum | |
CN104189291A (en) | Traditional Chinese medicine composition for treating upper respiratory infection | |
Jin et al. | Chinese Herbs for Pharyngitis Including COVID-19-Related Sore Throat | |
CN102657709A (en) | A traditional Chinese medicine for treating rhinitis | |
CN102406748B (en) | Chinese medicinal composition for treating child bronchitis | |
CN101829185B (en) | Medicinal composition for resisting influenza virus | |
CN1500505A (en) | Medication composition for children 's virus pneumonia and its preparation method | |
CN104547575A (en) | Traditional Chinese medicinal composition for treating capillary bronchitis and induced diarrhea and method for preparing composition | |
CN105125716A (en) | Traditional Chinese medicinal preparation for treating upper respiratory infection | |
CN102727747B (en) | Medicine for treating aplastic anemia through detoxification | |
CN104189610A (en) | Traditional Chinese medicine composition for treating bronchitis | |
CN108524623A (en) | Alleviate the Chinese patent drug of bronchiectasis pain | |
CN102018889A (en) | TCM preparation for treating wind-cold type of common cold |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130807 |